GI Cancers | Clinical

Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors

November 17, 2020

In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.

Marshall Recognizes Need for Collaboration During Pancreatic Cancer Awareness Month

November 13, 2020

In an interview with Targeted Oncology, John L. Marshall, MD, provided an overview of the evolution of treatments for patients with pancreatic cancer, as well as the current therapeutic approaches for these patients and what’s next for this treatment paradigm.

First-In-Class Targeted Therapy Shows Survival Benefit Advanced Gastric/GEJ Adenocarcinoma Subset

November 11, 2020

Three efficacy end points met pre-specified statistical significance in the phase 2 FIGHT study of bemarituzumab plus modified FOLFOX6 in patients with FGFR2b-positive non-HER2-positive frontline advanced gastric or gastroesophageal junction cancer.

New and Updated Data in GI Cancer Trials Show Continued Benefit With Targeted and Immunotherapy Agents

October 26, 2020

Historically, in gastrointestinal malignancies, chemotherapy and radiation were utilized to improve outcomes for patients. Although these treatments were effective, disease recurrence was always imminent, demonstrating a need for novel therapies.

FDA Grants Orphan Drug Designation to Novel Monoclonal Antibody in Multiple GI Malignancies

October 15, 2020

An Orphan Drug Designation had been granted by the FDA to the CD40 antagonistic monoclonal antibody, APX005M for the treatment esophageal and gastroesophageal junction cancer, as well as for the treatment of patients with pancreatic cancer.

Expert Highlights Importance of Biomarker Testing in Pancreatic Cancer

October 07, 2020

At ISGIO 2020, Michael J. Pishvaian, MD, PhD, discussed the importance of using standard-of-care chemotherapy and to test for actionable mutations in patients with pancreatic cancers, which can identify ways to individualize therapy for these patients.